On October 20, 2025 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) reported the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 ADC), were presented in a Poster Presentation at ESMO (Free ESMO Whitepaper) 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Poster Presentation:
Title: Phase I/II study of CLDN18.2 ADC ATG-022 in patients with advanced gastric/gastroesophageal junction cancer (CLINCH)
Abstract Number: 2907
Presentation Number: 2113P

ATG-022 and CLINCH Study Overview

ATG-022 is a CLDN18.2-targeted ADC with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload (DAR 4), ATG-022 has demonstrated potent activity across tumors with high/low/ultra-low CLDN18.2 expression.
The ongoing Phase I/II CLINCH study consists of dose escalation and dose expansion phases. In dose escalation, patients with advanced solid tumors regardless of CLDN18.2 expression receive ATG-022 (0.3-3.0 mg/kg Q3W) to evaluate safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥IHC 1+, 1%) patients are treated at 1.8 or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety.
Key Results Presented

Efficacy:
Among GC/GEJC patients with moderate/high CLDN18.2 expression (IHC 2+ >20%), the 2.4 mg/kg dose cohort observed 1 CR, 11 PRs and 15 SDs, resulting in 40% ORR (12/30) and 90% DCR (27/30). The median PFS was 6.97 months and the 12-month OS rate was 66.2%. In the 1.8 mg/kg dose cohort, there were 1 CR, 9 PRs, and 11 SDs, giving a 40% ORR (10/25) and 84% DCR (21/25).
Among GC/GEJC patients with low/ultra-low CLDN18.2 expression (IHC 2+ ≤20%), patients treated at the efficacious dose of 1.8-2.4 mg/kg achieved 1 CR and 5 PRs, resulting in 33.3% ORR (6/18) and 50%DCR (9/18). The CR patient has demonstrated durable response and has been on the study for 22+ months.
Safety:
At 2.4 mg/kg in the dose expansion, 45.8% of patients had ≥1 TEAEs, 60.4% of patients had grade ≥3 TEAEs.
In the dose-expansion phase, the 1.8 mg/kg cohort demonstrated excellent safety and tolerability, with only 13.6% of patients reporting serious TEAEs and 18.2% reporting Grade ≥3 TEAEs. The favorable safety profile of this dose level support its potential use in first-line combination regimens with chemotherapy and immune checkpoint inhibitors.
Conclusions and Outlook

ATG-022 demonstrated a manageable safety profile and encouraging antitumor effects in GC/GEJC adenocarcinoma patients with a broad range of CLDN18.2 expressions, thus supporting further clinical investigation in patients with variable CLDN18.2 expressions.
Preliminary efficacy has also been observed in other non-GI tumor types which will be reported at upcoming conferences.
The 2.4 mg/kg cohort showed a favorable safety profile, while the 1.8 mg/kg cohort demonstrated even better safety and tolerability. These findings provide strong support for advancing ATG-022 in combination with immune checkpoint inhibitors and chemotherapy in first-line treatment settings, paving the way to significantly expand its clinical reach and commercial potential.

(Press release, Antengene, OCT 20, 2025, View Source [SID1234656837])

On October 20, 2025 Sairopa, a clinical-stage biotechnology company developing innovative cancer immunotherapies, reported new clinical data on ADU-1604, its differentiated CTLA-4 blocking antibody, at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025, taking place October 17-21, 2025 in Berlin, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company presented a scientific poster showcasing significant clinical advances with ADU-1604 in melanoma patients who had previously failed PD-1 inhibitor therapy (n=27). The poster presentation featured the full results from the SRP-21C101 Phase 1 combined dose escalation and dose expansion clinical trial. Clinical efficacy was observed in 4/27 patients indicative of efficacy similar to other CTLA-4 inhibitors. Importantly, ADU-1604 showed a significantly milder safety profile as compared to existing CTLA-4 inhibitors, as evidenced by the reduced severity of immune-related adverse events.

"We are excited to share the clinical results from ADU-1604 in PD1 relapse/refractory melanoma with the international oncology community at ESMO (Free ESMO Whitepaper) Congress," said Laura Lassouw-Polman, Chief Operating Officer at Sairopa. "ADU-1604’s milder safety profile as compared to other CTLA-4 blocking agents will support its future use as combination agent, with PD-1 blocking agents and/or other agents. We are grateful to all patients, their families and investigators that supported our study."

(Press release, Sairopa, OCT 20, 2025, View Source [SID1234656822])

On October 20, 2025 HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, reported that new clinical data from HCB101, its differentiated, engineered SIRPα-Fc fusion protein, and the preclinical results from HCB301, its next-generation tri-specific checkpoint immunotherapy, will be presented at five major international oncology congresses in the fourth quarter of 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The upcoming presentations will showcase progress from HCB101, including both the HCB101-101 monotherapy (NCT05892718) and the HCB101-201 combination (NCT06771622) studies, as well as the preclinical data from HCB301, underscoring the company’s innovation in advancing next-generation innate immune checkpoint therapies.

Federation of Asian Clinical Oncology (FACO), October 24-25, 2025
– Two poster presentations on HCB101 monotherapy and HCB101 in combination with standard of care in advanced cancers
Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), November 5-9, 2025
– Two late-breaking poster presentations from HCB101-101 and HCB101-201, highlighting safety, pharmacology, and emerging efficacy signals
– One poster presentation from HCB301, revealing the first-time the preclinical data from HanchorBio’s novel tri-specific fusion protein targeting CD47-SIRPα, PD-1, and TGFb pathways
ESMO Asia Congress, December 5-7, 2025
– One abstract updating the results from HCB101-101, demonstrating safety and activity across solid tumors and hematologic malignancies
American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, December 6-9, 2025
– Poster presentation of the first-in-human Phase 1 study of HCB101 in relapsed/refractory non-Hodgkin lymphoma
ESMO Immuno-Oncology Congress (ESMO-IO), December 10-12, 2025
– One abstract integrating the HCB101 monotherapy and combination data across multiple solid tumor indications
"Presenting across five major oncology meetings in one quarter underscores both the breadth and pace of HCB101’s clinical progress," said Scott Liu, Ph.D., Chairman, CEO, and Founder of HanchorBio. "HCB101 continues to validate our differentiated approach to CD47-SIRPα blockade, while the first preclinical data from HCB301 showcase the innovation of our FBDB platform in advancing next-generation, multi-checkpoint therapies. Together, they highlight HanchorBio’s commitment to delivering transformative treatments for patients with difficult-to-treat cancers and advancing the next generation of immunotherapies."

About HCB101: A Differentiated CD47-SIRPα Blockade
HCB101 is a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio’s proprietary FBDB platform. It is engineered for selective CD47 targeting with low red blood cell (RBC) binding, thereby avoiding the anemia and thrombocytopenia commonly associated with earlier anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging.

Key Differentiators of HCB101:

Enhanced safety: Demonstrates a cytopenia-sparing profile, with no dose-limiting toxicities observed up to 24 mg/kg and receptor occupancy >90% at ≥1.28 mg/kg, supporting a broad therapeutic window.
Robust immune activation: Engineered to enhance ADCP and bridge innate-to-adaptive immunity, with evidence of durable immune-mediated tumor control in monotherapy.
Broad tumor applicability: Demonstrated activity across >80 PDX and CDX preclinical models, with early clinical signals in gastric cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, non-Hodgkin lymphoma, and ovarian cancer.
Clinical translation: Shows durable disease control as monotherapy and a 100% confirmed partial response rate (6/6) in second-line gastric cancer when combined with ramucirumab and paclitaxel, with additional confirmed responses in first-line TNBC and second-line HNSCC, substantially exceeding historical benchmarks.
About HCB301: a Tri-Specific Checkpoint Immunotherapy
HCB301 is HanchorBio’s next-generation immunotherapy designed to integrate three synergistic mechanisms into a single molecule: CD47-SIRPα blockade to activate macrophage-mediated phagocytosis, PD-1 inhibition to restore exhausted T cells, and TGF-b pathway suppression to improve tumor micro-environment. Developed using the proprietary FBDB platform, HCB301 represents a next-generation approach to multi-checkpoint immunotherapy. Preclinical studies demonstrated enhanced immune activation and potent antitumor activities, and the first results will be presented at SITC (Free SITC Whitepaper) 2025.

(Press release, Hanchor Bio, OCT 20, 2025, View Source [SID1234656838])

On October 20, 2025 Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), reported the completion of its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona’s Targeted Hyperthermia Therapy ("THT"). Ten advanced-stage patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited into this early feasibility study. Under the study protocol, patients had up to four tumors treated with Sona’s THT on days one and eight of the study. By day 15, 8/10 patients experienced a significant clinical response to treatment with a majority (6/8) showing no detectable residual melanoma in representative, biopsied tumors, and two patients showing no response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

David Regan, Sona’s CEO, commented, "These favorable results—demonstrated in the majority of treated patients—show that Sona’s THT therapy has successfully eliminated melanoma in tumors where leading treatments had previously failed. This outcome has exceeded our expectations and delivered on our commitment to investors to produce human efficacy data quickly. Based on findings from this study, we are preparing for a Canadian clinical trial that will provide deeper insights into the biological potential of our THT as we prepare to expand its clinical application into a broader range of solid tumor cancers. An application for an investigational testing authorization ("ITA") has been made to Health Canada to permit this next clinical study for which we have already received research ethics board approval."

The study’s principal investigator, Dr. Carlos Rojas, Executive Director of the Bradford Hill Clinical Cancer Research Center commented, "We were very impressed by the rapid and measurable responses observed in patients who had exhausted standard immunotherapy options. These outcomes have provided meaningful hope for the patients enrolled."

Dr. Carman Giacomantonio, Sona’s CMO, commented, "These tremendous results validate our earlier, published preclinical findings and provide compelling clinical evidence of the efficacy and tolerability of Sona’s novel Targeted Hyperthermia Therapy in human cancer. Although this study was not powered to determine response rates, eight out of ten patients experienced responses in a treated tumor with six out of those eight patients’ biopsied tumors showing a complete response – commands one’s attention. Equally impressive is the observation that these responses were confirmed after only two weeks from the initial treatment. This, to my knowledge, is unprecedented."

Safety and tolerability data also showed favourable results. One stage IV patient reported a serious adverse event during the trial that investigators determined to be unrelated to THT, which ultimately resolved. Also, two stage IV patients expired shortly following completion of the study period due to distant disease progression. Another aim of the study was to capture clinician-reported and patient-reported experience with the physical delivery of THT with a view to improving the overall clinical delivery of Sona’s THT. To this end, significant data was captured highlighting opportunities for design and application enhancement that will be applied and evaluated in future studies.

The Company also announces that its Chief Scientific Officer, Len Pagliaro, PhD. Is stepping back from an operational role. "Developing a powerful but gentle cancer therapy that uses nanotechnology to stimulate the immune system, and has the potential to transform lives, has been the focus of the past 16 years of my career." said Dr. Pagliaro. "These remarkable first-in-human results mark the fulfillment of that vision. I now look forward to continuing to support the Company as a member of Sona’s board of directors."

Investor Webinar details:

The Company is also pleased to announce that it will host a webinar on Monday, October 20th at noon EST to discuss these results in more detail and outline plans for the coming year. Interested parties can register here: http://bit.ly/3JcFls5. A recording of the webinar will be made available following the webinar in the Investor Information section of the Company’s website."

(Press release, Sona Nanotech, OCT 20, 2025, View Source [SID1234656823])

On October 20, 2025 Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), reported that the companies have entered into a global collaboration agreement to develop, manufacture and commercialize two ADC assets: TJ108, bispecific and dual-payload ADC, and another asset to be named. In addition, Samsung Bioepis will receive an exclusive license from Phrontline for one topoisomerase-1 inhibitor (TOP1i) payload which is applied to Samsung Bioepis’ ADC pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Phrontline’s TJ108 is TOP1i and tubulin inhibitor-based ADC directed against Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 3 (HER3), targets that are overexpressed in a variety of cancers, which contribute to aggressive growth and metastasis.i,ii

Under the terms of the agreement, Phrontline will receive an upfront payment and will be eligible to receive additional milestone payments tied to development and regulatory achievements.

"We are excited to partner with Phrontline in developing and advancing differentiated ADCs that target a broad range of indications," said Kyung-Ah Kim, President and Chief Executive Officer, at Samsung Bioepis. "We will continue to explore new business opportunities to address unmet needs of patients, leveraging our proven development platforms."

"Phrontline has honed its bispecific targeting technology to enhance payload delivery efficiency and has advanced an innovative dual-linker payload (DLP) platform that enables the simultaneous delivery of two payloads with balanced potency and distinct mechanisms of action through a branched-linker architecture, while supporting scalable and efficient one-step conjugation. This partnership accelerates our vision to establish bispecific, dual-payload ADCs as a new class of precision oncology medicines," said Zhaoyuan ‘Tony’ Chen, Founder and Chief Executive Officer of Phrontline Biopharma. "Together with Samsung Bioepis, we will scale the DLP platform — beginning with TJ108 — to address resistance, heterogeneity, and durability challenges that limit today’s single-payload, single-target ADCs."

Samsung Bioepis is expanding its pipeline beyond biosimilars to fulfill its mission of broadening patient access to treatments in the areas of unmet therapeutic needs. The development of ADCs could add into the company’s broad spectrum of therapeutic portfolio that covers immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.

(Press release, Phrontline Biopharma, OCT 20, 2025, View Source [SID1234656839])